VDR and prostate cancer: Some in vitro studies using VDR-expressing prostate cancer LNCaP cells reported that EB108928, a potent analogue of 1,25D3 as well as 1,25D329 has inhibitory effects on the growth of cancer cells, implying that 1,25D3 might be effective as a therapeutic reagent for prostate cancer in some cases.